InveniAI Featured in The Guardian’s Rare Disease Campaign to Showcase how Artificial Intelligence can be Leveraged to Create Patient Solutions
01 mars 2019 09h00 HE
|
InveniAI
GUILFORD, Conn., March 01, 2019 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform...
Amicus Establishes Global Research and Gene Therapy Center of Excellence in Philadelphia
26 févr. 2019 07h00 HE
|
Amicus Therapeutics, Inc.
New 75,000 sq. ft. State of the Art Facility in uCity Square Adjacent to Penn Campus Strengthens Amicus Capabilities as a Leading Global Rare Disease Biotechnology Company CRANBURY, N.J. and...
BIOMEDevice Boston 2019 Announces Conference Content: Bringing Technology & Product Development Best Practices Together for Successful Innovation
21 févr. 2019 08h02 HE
|
Advanced Manufacturing Boston
SANTA MONICA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BIOMEDevice Boston, New England’s premier medical technology event, is headed to the Boston Convention Center May 15-16, 2019, offering an...
U.S. Continues to Lead New Drug R&D, but Asia-Pacific is Starting to Rise, According to the Tufts Center for the Study of Drug Development
08 janv. 2019 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Recent launches of new active substances (NAS) and a strong R&D pipeline indicate that recent global drug development not only has been robust, but also...
UPDATE - Hikma Pharmaceutical Plants Sold to Investor Group
02 janv. 2019 17h27 HE
|
Gordon Brothers
Eatontown, New Jersey, Jan. 02, 2019 (GLOBE NEWSWIRE) -- A joint venture between Gordon Brothers and New Mill Capital Holdings has acquired three buildings from Hikma Pharmaceuticals in the...
Hikma Pharmaceutical Plants Sold to Investor Group
02 janv. 2019 16h39 HE
|
Gordon Brothers
Eatontown, New Jersey, Jan. 02, 2019 (GLOBE NEWSWIRE) -- A joint venture between Gordon Brothers (www.gordonbrothers.com) and New Mill Capital Holdings (www.newmillcapital.com) has acquired three...
Global Biotech Product Development Expected to Continue Its Multi-Decade Surge, According to the Tufts Center for the Study of Drug Development
13 nov. 2018 09h00 HE
|
Tufts Center for the Study of Drug Development
BOSTON, Nov. 13, 2018 (GLOBE NEWSWIRE) -- With more than 500 Phase III clinical trials now underway for biotech products worldwide, the multi-decade surge in new biopharmaceutical approvals is...
Revive Therapeutics Announces FDA Grants Orphan Drug Designation for Cannabidiol in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation
07 nov. 2018 08h00 HE
|
Revive Therapeutics Ltd.
TORONTO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (TSX VENTURE: RVV) (OTCQB: RVVTF) (FSE:31R) ("Revive" or the “Company”), a specialty cannabis company focused on the research,...
InveniAI®’s Innovation Monitoring Platform, AlphaMeld™, Witnesses Rapid Uptake in BioPharma and Adjacencies
17 oct. 2018 12h00 HE
|
InveniAI
Platform built to detect the earliest signs of innovation in real-time and across industries BRANFORD, Conn., Oct. 17, 2018 (GLOBE NEWSWIRE) -- InveniAI® Corporation, a global leader in pioneering...
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement
16 oct. 2018 02h13 HE
|
NANOBIOTIX
Nanobiotix reçoit un versement initial de 16 millions d’euros au titre du prêt accordé par la Banque Européenne d’Investissement Le produit sera utilisé pour accélérer le développement du produit...